Information:
Fel:
ID
34005
Beskrivning
Phase II Study of SBRT as Treatment for Oligometastases in Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02192788
Länk
https://clinicaltrials.gov/show/NCT02192788
Nyckelord
Versioner (1)
- 2019-01-10 2019-01-10 -
Rättsinnehavare
See clinicaltrials.gov
Uppladdad den
10 januari 2019
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Oligometastatic Prostate Cancer NCT02192788
Eligibility Oligometastatic Prostate Cancer NCT02192788
- StudyEvent: Eligibility
Similar models
Eligibility Oligometastatic Prostate Cancer NCT02192788
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Prostate carcinoma | Neoplasm Metastasis Few Post Primary treatment | Recurrence Few Post Primary treatment
Item
patients with histologically confirmed prostate cancer, who are currently being oligometastases / oligorrecurrencia after primary treatment for their disease.
boolean
C0600139 (UMLS CUI [1])
C0027627 (UMLS CUI [2,1])
C0205388 (UMLS CUI [2,2])
C0687676 (UMLS CUI [2,3])
C1708063 (UMLS CUI [2,4])
C0034897 (UMLS CUI [3,1])
C0205388 (UMLS CUI [3,2])
C0687676 (UMLS CUI [3,3])
C1708063 (UMLS CUI [3,4])
C0027627 (UMLS CUI [2,1])
C0205388 (UMLS CUI [2,2])
C0687676 (UMLS CUI [2,3])
C1708063 (UMLS CUI [2,4])
C0034897 (UMLS CUI [3,1])
C0205388 (UMLS CUI [3,2])
C0687676 (UMLS CUI [3,3])
C1708063 (UMLS CUI [3,4])
Age
Item
aged ≥ 18 years
boolean
C0001779 (UMLS CUI [1])
Time Interval Recurrence Biochemical
Item
time to biochemical recurrence more than 1 year
boolean
C0872291 (UMLS CUI [1,1])
C0034897 (UMLS CUI [1,2])
C0205474 (UMLS CUI [1,3])
C0034897 (UMLS CUI [1,2])
C0205474 (UMLS CUI [1,3])
Prostate-Specific Antigen Doubling Time
Item
psa doubling time> 3 months
boolean
C0138741 (UMLS CUI [1,1])
C2986483 (UMLS CUI [1,2])
C2986483 (UMLS CUI [1,2])
Secondary malignant neoplasm of bone Location Quantity | Secondary malignant neoplasm of spinal cord | Secondary malignant neoplasm of lymph node
Item
less than 5 bone metastases location (including spinal) or lymph node.
boolean
C0153690 (UMLS CUI [1,1])
C0450429 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C0347016 (UMLS CUI [2])
C0686619 (UMLS CUI [3])
C0450429 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C0347016 (UMLS CUI [2])
C0686619 (UMLS CUI [3])
Neoplasm Metastasis Other Absent | Recurrence Other Absent | Choline PET | NMR
Item
without other metastases or recurrences by choline pet or / and nmr diffusion length.
boolean
C0027627 (UMLS CUI [1,1])
C0205394 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,3])
C0034897 (UMLS CUI [2,1])
C0205394 (UMLS CUI [2,2])
C0332197 (UMLS CUI [2,3])
C0008405 (UMLS CUI [3,1])
C0032743 (UMLS CUI [3,2])
C0024485 (UMLS CUI [4])
C0205394 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,3])
C0034897 (UMLS CUI [2,1])
C0205394 (UMLS CUI [2,2])
C0332197 (UMLS CUI [2,3])
C0008405 (UMLS CUI [3,1])
C0032743 (UMLS CUI [3,2])
C0024485 (UMLS CUI [4])
Informed Consent
Item
signed and dated written informed consent form.
boolean
C0021430 (UMLS CUI [1])
abiraterone | enzalutamide | Chemotherapy | Immunotherapy | Radioisotopes
Item
patients currently treatment with abiraterone, enzalutamide, chemotherapy, immunotherapy or radioisotopes.
boolean
C0754011 (UMLS CUI [1])
C3496793 (UMLS CUI [2])
C0392920 (UMLS CUI [3])
C0021083 (UMLS CUI [4])
C0034595 (UMLS CUI [5])
C3496793 (UMLS CUI [2])
C0392920 (UMLS CUI [3])
C0021083 (UMLS CUI [4])
C0034595 (UMLS CUI [5])
Protocol Compliance Unwilling | Protocol Compliance Unable
Item
patients unwilling or unable to comply with protocol requirements and scheduled visits.
boolean
C0525058 (UMLS CUI [1,1])
C0558080 (UMLS CUI [1,2])
C0525058 (UMLS CUI [2,1])
C1299582 (UMLS CUI [2,2])
C0558080 (UMLS CUI [1,2])
C0525058 (UMLS CUI [2,1])
C1299582 (UMLS CUI [2,2])